Desvenlafaxine succinate  (Synonyms: O-Desmethylvenlafaxine succinate; Wy-45233 succinate)

Desvenlafaxine succinate, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC₅₀ values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine succinate (DVS) shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter^[1][2].

IC50: 47.3 nM (hSERT), 531.3 nM (hNET)^[1].

Desvenlafaxine succinate has the potential to inhibit CYP2D6, which could result in increased concentrations of drugs metabolized through this pathway. Desvenlafaxine succinate also induces CYP3A4, which could impact the metabolism of drugs metabolized via this enzyme^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Desvenlafaxine succinate (30 mg/kg, orally) significantly increases extracellular NE levels but had no effect on DA levels using microdialysis^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

381.46

C₂₀H₃₁NO₆

448904-47-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Darlene C Deecher, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65.  [Content Brief]

  [2]. Michael A Sopko Jr, et al. Desvenlafaxine: another "me too" drug? Ann Pharmacother. 2008 Oct;42(10):1439-46.  [Content Brief]